Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Executive Summary
Celltech Chiroscience Chirocaine (levobupivacaine) Phase IV commitments include the completion of a cardiovascular resuscitation study in dogs. Chirocaine, which cleared FDA August 5 with an indication for surgical anesthesia and pain management in adults, was deemed "approvable" in February.
You may also be interested in...
Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Approved labeling for Chiroscience's long-acting local anesthetic Chirocaine (levobupivacaine) indicates a possible cardiac and central nervous system safety advantage over bupivacaine based on animal data.
Chiroscience Chirocaine Labeling Cites Possible Safety Advantage
Approved labeling for Chiroscience's long-acting local anesthetic Chirocaine (levobupivacaine) indicates a possible cardiac and central nervous system safety advantage over bupivacaine based on animal data.
Purdue Boosts Early-Stage Neuroscience Research With CoCensys Buy
Purdue Pharma is boosting its early-stage research with the purchase of the neuroscience firm CoCensys for a total cash price of $9.5 mil.